Answers are grounded in this paper and cite their sources.
The use of Artificial Intelligence (AI) is becoming increasingly prevalent in drug discovery and development and holds the potential to address the challenges in ADC development. AI requires substantial amounts of high-quality data to make reliable predictions of a novel ADC’s safety and efficacy. However, since this therapeutic area is still fairly new, there is limited data available to meet all the challenges of ADC development through AI. In such a scenario, enriching AI with knowledge (hybrid AI) is a very promising approach and provides high-accuracy predictions even in data-limited scenarios.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: